Repligen (NASDAQ:RGEN) Shares Up 5.9% – What’s Next?

Repligen Corporation (NASDAQ:RGEN) was up 5.9% during trading on Thursday . The stock traded as high as $186.80 and last traded at $186.80. 645,660 shares changed hands during trading, a decline of 36% from the average session volume of 1,015,015 shares. The stock had previously closed at $176.36.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Royal Bank Of Canada started coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price on the stock. Wolfe Research began coverage on shares of Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. Finally, Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Repligen has an average rating of “Buy” and a consensus price target of $166.43.

Repligen Trading Up 0.5%

The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The business has a 50-day simple moving average of $147.16 and a 200-day simple moving average of $131.88. The company has a market cap of $10.22 billion, a PE ratio of 248.12, a price-to-earnings-growth ratio of 3.29 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the business posted $0.26 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently bought and sold shares of the business. Avidity Partners Management LP boosted its position in Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock valued at $9,166,000 after buying an additional 27,500 shares during the period. Swedbank AB purchased a new stake in shares of Repligen during the fourth quarter worth $4,146,000. Conestoga Capital Advisors LLC increased its position in shares of Repligen by 10.6% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock worth $173,360,000 after acquiring an additional 101,062 shares during the period. Jennison Associates LLC purchased a new stake in shares of Repligen during the fourth quarter worth $20,253,000. Finally, Wasatch Advisors LP acquired a new stake in shares of Repligen in the first quarter valued at $146,513,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.